Literature DB >> 11231185

Trends in antimicrobial resistance and serotype distribution of blood and cerebrospinal fluid isolates of Streptococcus pneumoniae in South Africa, 1991-1998.

A D Wasas, K P Klugman.   

Abstract

OBJECTIVE: Since 1979, the South African Institute for Medical Research (SAIMR) has served as the national reference center for pneumococcal serotyping and monitoring of antibiotic resistance trends. This study documents trends in antimicrobial resistance in pneumococci isolated from blood or cerebrospinal fluid (CSF) between 1991 and 1998 in South Africa.
METHODS: Pneumococcal isolates (n = 7406) from either blood or CSF were sent to the SAIMR reference laboratory for serotyping. The isolates were evaluated for resistance to penicillin, chloramphenicol, tetracycline, erythromycin, clindamycin, and rifampicin.
RESULTS: Resistance to one or more antibiotics increased significantly from 19% in 1991 to 1994 to 25% in 1995 to 1998 in all ages, and in children from 32% to 38% (P < 10[-6]). Although penicillin resistance did not increase in children (28.1% vs. 28.9%), penicillin resistance in all ages increased from 9.6% to 18.0%. Significant increases in resistance to chloramphenicol, tetracycline, erythromycin, and rifampicin also were seen in both groups. Multiple resistance increased significantly, from 2.2% to 3.8%. The proportion of isolates with intermediate or high-level penicillin resistance remained constant during the surveillance period. Erythromycin resistance, predominantly expressed as simultaneous resistance to erythromycin and clindamycin, increased from 1.6% to 2.6%. The percentage of erythromycin-resistant isolates that were resistance to erythromycin alone increased from 10.6% to 28.7%, suggesting the emergence of mefE-mediated resistance. In children 2 years of age and younger, although serogroup 6 remained the most common, there were significant increases in serogroups 19, 18, and 13. The percentage of the total invasive pneumococcal disease in this population that is caused by serogroups found in the nonavalent pneumococcal conjugate vaccine (serogroups 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F) increased from 72% to 91%.
CONCLUSIONS: Antibiotic resistance in the pneumococcus is increasing in South Africa, although the proportion of strains with high-level penicillin resistance has not increased. New conjugate vaccines may not only decrease the burden of all pneumococcal disease but, in addition, lower the incidence of antibiotic-resistant disease in South Africa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11231185     DOI: 10.1016/s1201-9712(00)90112-7

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  14 in total

1.  Molecular epidemiology of pneumococcal carriage among children with upper respiratory tract infections in Hanoi, Vietnam.

Authors:  D Bogaert; N T Ha; M Sluijter; N Lemmens; R De Groot; P W M Hermans
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Factors associated with ceftriaxone nonsusceptibility of Streptococcus pneumoniae: analysis of South African national surveillance data, 2003 to 2010.

Authors:  Claire von Mollendorf; Cheryl Cohen; Linda de Gouveia; Vanessa Quan; Susan Meiring; Charles Feldman; Keith P Klugman; Anne von Gottberg
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae.

Authors:  Reiko Kobayashi; Mami Konomi; Keiko Hasegawa; Miyuki Morozumi; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008.

Authors:  Penny Crowther-Gibson; Cheryl Cohen; Keith P Klugman; Linda de Gouveia; Anne von Gottberg
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

5.  Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility.

Authors:  David B Blossom; Grace Namayanja-Kaye; Joan Nankya-Mutyoba; John B Mukasa; Henry Bakka; Sandra Rwambuya; Anne Windau; Saralee Bajaksouzian; Courtney J Walker; Moses L Joloba; Cissy Kityo; Peter Mugyenyi; Christopher C Whalen; Michael R Jacobs; Robert A Salata
Journal:  Int J Infect Dis       Date:  2006-09-25       Impact factor: 3.623

6.  Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae.

Authors:  Sarah L Batt; Bambos M Charalambous; Anthony W Solomon; Charles Knirsch; Patrick A Massae; Salesia Safari; Noel E Sam; Dean Everett; David C W Mabey; Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

7.  Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002.

Authors:  Kimiko Ubukata; Naoko Chiba; Keiko Hasegawa; Reiko Kobayashi; Satoshi Iwata; Keisuke Sunakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin.

Authors:  Stephanie J Schrag; Lesley McGee; Cynthia G Whitney; Bernard Beall; Allen S Craig; Miriam E Choate; James H Jorgensen; Richard R Facklam; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Drug-resistant Streptococcus pneumoniae in Community-acquired Pneumonia.

Authors:  Michael Henry; Howard L. Leaf
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

10.  Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women.

Authors:  C J Gill; V Mwanakasale; M P Fox; R Chilengi; M Tembo; M Nsofwa; V Chalwe; L Mwananyanda; D Mukwamataba; B Malilwe; D Champo; W B Macleod; D M Thea; D H Hamer
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.